

Booking Date	27/09/2024	Patient ID : 012409270046	Reported on 03/10/2024
Name	Neena Juneja	Age : 56 Years	Sex - Female
Ref By	Dr. Amish Vora		

**DIAGNOSIS:** Her2 IHC 2+ (Equivocal) Breast Cancer IDC


**METHODOLOGY:** Fluorescence *in situ* Hybridization (FISH)

**PROBE NAME:** HEALTHCARE HER2/CEP17 dual color probe.

### FISH:

Total number of cells scored	100
Total number of HER2 signals	2000
Total number of CEP17 signals	300
Average HER2 signals/cell	20.00
Computed Ratio	6.67

**Positive**



Cells showing HER2 signals (orange) and CEP17 signals (green).

### CLINICAL INTERPRETATION:

1. Positive for HER2/neu amplification as per ASCO 2018 guidelines.
2. Her2:CEP17 ratio is  $\geq 2$  and Average Her2 signals  $\geq 4$  (Group 1).

### RECOMMENDATION:

**Please Note:** Evaluation of this specimen shows abnormal hybridization pattern. These findings are indicative that the patient is eligible for anti HER2 therapy (Trastuzumab +/- Pertuzumab). Her2 gene amplification is seen 18 to 20% of invasive breast cancers. These tumours show increased over all survival rate with Her2 targeted therapy such as Trastuzumab +/- Pertuzumab. It has been recognized as a poor prognosis indicator in early breast cancer. In cases where tumor heterogeneity is present, analysis of HER2 FISH on additional blocks is recommended for conclusive result.